Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $41.5 million.

  • Entrada Therapeutics' Shares Outstanding (Weighted Average) rose 205.01% to $41.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.5 million, marking a year-over-year increase of 205.01%. This contributed to the annual value of $37.3 million for FY2024, which is 1287.75% up from last year.
  • Per Entrada Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $41.5 million for Q3 2025, which was up 205.01% from $41.3 million recorded in Q2 2025.
  • Entrada Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $41.5 million during Q3 2025, with a 5-year trough of $31.2 million in Q1 2022.
  • In the last 4 years, Entrada Therapeutics' Shares Outstanding (Weighted Average) had a median value of $33.3 million in 2023 and averaged $35.1 million.
  • The largest annual percentage gain for Entrada Therapeutics' Shares Outstanding (Weighted Average) in the last 5 years was 2261.89% (2025), contrasted with its biggest fall of 205.01% (2025).
  • Over the past 4 years, Entrada Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $31.3 million in 2022, then rose by 5.61% to $33.1 million in 2023, then rose by 12.88% to $37.3 million in 2024, then rose by 11.14% to $41.5 million in 2025.
  • Its last three reported values are $41.5 million in Q3 2025, $41.3 million for Q2 2025, and $41.1 million during Q1 2025.